SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

(2018) Dietrich A. Ruess et al.   NATURE MEDICINE

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

(2017) Andrew M. Waters et al.   Science Signaling

Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies

(2017) Andrew M. Waters et al.   Science Signaling

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression

(2016) Tobias Eggert et al.   CANCER CELL

Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor

(2016) Jorge Garcia Fortanet et al.   JOURNAL OF MEDICINAL CHEMISTRY

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

(2016) Ying-Nan P. Chen et al.   NATURE

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

(2016) Chiara Ambrogio et al.   NATURE MEDICINE

Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice

(2015) L. Lan et al.   EMBO JOURNAL

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

(2015) J. C. Hunter et al.   MOLECULAR CANCER RESEARCH

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs

(2015) Anirudh Prahallad et al.   Cell Reports

Dragging Ras Back in the Ring

(2014) Andrew G. Stephen et al.   CANCER CELL

Gene expression profiling of replicative and induced senescence

(2014) Maggie Purcell et al.   CELL CYCLE

The clinical development of MEK inhibitors

(2014) Yujie Zhao et al.   Nature Reviews Clinical Oncology

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

A Missing Link in Genotype-Directed Cancer Therapy

(2012) René Bernards   CELL

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network

(2008) Thomas Kuilman et al.   CELL

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical pathways in cellular senescence and immortalization revealed by gene expression profiling

(2008) A L Fridman et al.   ONCOGENE

Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats

(2008) M. J. Herold et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor

(2008) Jean-Philippe Coppé et al.   PLOS BIOLOGY